News | September 26, 2014

EDUCAT Study Shows Patient Education Increases Acceptance of Home Monitoring and Reduces Patient Anxiety

September 26, 2014 — Biotronik announced that the results of the EDUCAT study support a link between patient comprehension and clinical acceptance regarding remote monitoring. The study underscores the benefits of Biotronik Home Monitoring, showing that deepening patients’ knowledge of remote monitoring technology increases their understanding of its benefits. In turn, better understanding can lead to greater success in therapies that use this technology, while also lessening the anxiety and uncertainty associated with heart disease.

The Patient Education and Home Monitoring (EDUCAT) study was a prospective, observational, multicenter study of 571 enrolled patients who were implanted with a Biotronik Lumax ICD (implantable cardioverter device) and remotely followed for six months. Patients were asked to fill out two questionnaires: Q1, given to patients at the time of study enrollment and intended to be completed anonymously after one month, evaluated the quality of training delivered at individual implant centers. Q2, completed anonymously six months after implant, measured the anxiety of the patient as well as their acceptance of Home Monitoring.

According to the study, better comprehension of the uses of remote monitoring corresponded with a number of positive patient impressions. Home installation of the CardioMessenger device, which receives signals from the implant and transmits them to the physician, was stress-free in 93 percent of patients. Although 99 percent of patients described the device as “useful,” patients who understood the system better were more likely to describe it as “unobtrusive, simple, small and reassuring.” Finally, 98 percent of patients even considered using Home Monitoring after the study’s completion, demonstrating that the technology can be easily adopted into patients’ daily lives. Furthermore, the EDUCAT results indicate that improving patient comprehension is relatively simple and straightforward: most of the methods trainers used in informing patients are already standard in post-implant communication.

“Although Home Monitoring is a fully-automated system that requires no patient interaction, our study has shown that patient trust in such a system greatly improves its success,” said principal investigator Gabriel Laurent, M.D., Ph.D., University Hospital Center Le Bocage, Dijon, France. “Heart conditions can be difficult to manage, and as a result, many patients report undue amounts of stress that may negatively impact their quality of life. The better we are able to explain such a system to them, the more likely patients are to see it as a reminder that caregivers are standing by.”

For more information:

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init